Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer

Journal of Clinical Oncology

Volumn 34, Issue 24, 2016, Pages 2835-2842

  Rusthoven, Chad G ^a   Jones, Bernard L ^a   Flaig, Thomas W ^a   Crawford, E David ^a   Koshy, Matthew ^b,c   Sher, David J ^d   Mahmood, Usama ^e   Chen, Ronald C ^f   Chapin, Brian F ^e   Kavanagh, Brian D ^a   Pugh, Thomas J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLACK PERSON; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CAUCASIAN; CHARLSON DEYO COMORBIDITY SCORE; COHORT ANALYSIS; COMORBIDITY ASSESSMENT; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICALLY UNINSURED; MEDICARE; METASTATIC PROSTATE CANCER; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; EPIDEMIOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 84982085654     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.4788     Document Type: Article

References (40)

1. Bayne CE, Williams SB, Cooperberg MR, et al: Treatment of the primary tumor in metastatic prostate cancer: current concepts and future perspectives. Eur Urol doi:10.1016/j.eururo.2015.04.036
2. Culp SH, Schellhammer PF, Williams MB: Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65:1058-1066, 2014
3. Fossati N, Trinh QD, Sammon J, et al: Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: A SEER-based study. Eur Urol 67:3-6, 2015
4. Gratzke C, Engel J, Stief CG: Role of radical prostatectomy in metastatic prostate cancer: Data from the Munich Cancer Registry. Eur Urol 66:602-603, 2014
5. Satkunasivam R, Kim AE, Desai M, et al: Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: A SEER-Medicare analysis. J Urol 194:378-385, 2015
6. Cho Y, Chang JS, Rha KH, et al: Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis? PLoS One 11:e0147191, 2016
7. Al-Mamgani A, Heemsbergen WD, Peeters ST, et al: Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73:685-691, 2009
8. Mottet N, Peneau M, Mazeron JJ, et al: Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: An open randomised phase 3 trial. Eur Urol 62:213-219, 2012
9. Warde P, Mason M, Ding K, et al: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet 378:2104-2111, 2011
10. Widmark A, Klepp O, Solberg A, et al: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 373:301-308, 2009
11. James ND, Spears MR, Clarke NW, et al: Impact of node status and radiotherapy on failure-free survival in patients with newly-diagnosed nonmetastatic prostate cancer: Data from.690 patients in the control arm of the STAMPEDE trial. Int J Radiat Oncol Biol Phys 90:S13, 2014
12. Lin CC, Gray PJ, Jemal A, et al: Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst 107:djv119, 2015
13. Rusthoven CG, Carlson JA, Waxweiler TV, et al: The impact of definitive local therapy for lymph node-positive prostate cancer: A population-based study. Int J Radiat Oncol Biol Phys 88:1064-1073, 2014
14. Bilimoria KY, Stewart AK, Winchester DP, et al: The National Cancer Data Base: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15:683-690, 2008
15. Kleinbaum DG, Klein M. Evaluating the proportional hazards assumption, In: Kleinbaum DG, Klein M (eds), Survival analysis: A Self-Learning Text, Third Edition. New York, NY, Springer, 2012 164-187.
16. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
17. Austin PC: Optimal caliperwidths for propensityscore matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150-161, 2011
18. Cochran WG, Rubin DB: Controlling bias in observational studies: A review. Sankhya Ser A 35:417-446, 1973
19. Ciampi A, Hogg SA, McKinney S, et al: RECPAM: A computer program for recursive partition and amalgamation for censored survival data and other situations frequently occurring in biostatistics. I. Methods and program features. Comput Methods Programs Biomed 26:239-256, 1988
20. James ND, Sydes MR, Clarke NW, et al: Addition of docetaxel, zoledronic acid, or both to firstline long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163-1177, 2016
21. Sweeney CJ, Chen Y-H, Carducci M, et al: Chemohormonal therapy in metastatic hormonesensitive prostate cancer. N Engl J Med 373:737-746, 2015
22. The National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Prostate cancer. v2. 2016. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#srostate
23. Niibe Y, Hayakawa K: Oligometastases and oligo-recurrence: The new era of cancer therapy. Jpn J Clin Oncol 40:107-111, 2010
24. Aparicio AM, Shen L, Tapia EL, et al: Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res 22:1520-1530, 2016
25. Mahal BA, Aizer AA, Efstathiou JA, et al: Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer 122:78-83, 2016
26. Kadmon D, Heston WD, Fair WR: Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol 127:1238-1242, 1982
27. Hartford AC, Gohongi T, Fukumura D, et al: Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: Potential role of host-tumor interaction. Cancer Res 60:2128-2131, 2000
28. Weckermann D, Polzer B, Ragg T, et al: Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 27:1549-1556, 2009
29. Kaplan RN, Riba RD, Zacharoulis S, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827, 2005
30. Tzelepi V, Efstathiou E, Wen S, et al: Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 29:2574-2581, 2011
31. Thompson IM, Tangen C, Basler J, et al: Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 168:1008-1012, 2002
32. Coen JJ, Zietman AL, Thakral H, et al: Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases. J Clin Oncol 20:3199-3205, 2002
33. Cifuentes FF, Valenzuela RH, Contreras HR, et al: Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer. Oncol Rep 34:2837-2844, 2015
34. Hong MK, Macintyre G, Wedge DC, et al: Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 6:6605, 2015
35. Flanigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655-1659, 2001
36. Mickisch GHJ, Garin A, Van Poppel H, et al: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: S randomised trial. Lancet 358:966-970, 2001
37. The National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Kidney cancer. v2. 2016. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#kidney
38. Ruiterkamp J, Voogd AC, Bosscha K, et al: Impact of breast surgery on survival in patients with distant metastases at initial presentation: A systematic review of the literature. Breast Cancer Res Treat 120:9-16, 2010
39. Badwe R, Hawaldar R, Nair N, et al: Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial. Lancet Oncol 16:1380-1388, 2015
40. Soran A, Ozmen V, Ozbas S, et al: Abstract S2-03: early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01). Cancer Res 73:S2-03, 2013